MULTIPLE MYELOMA

Kenneth C. Anderson, MD, discusses the therapies for patients who have multiple myeloma and have developed drug resistance.

The FDA granted approval to belantamab mafodotin-blmf for the treatment of patients with relapsed or refractory multiple myeloma who previously received treatment with at least 4 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

In an interview with Targeted Oncology, Hearn Jay Cho, MD, PhD, and Irene M. Ghobrial, MD, both discussed the importance of the CureCloud study for the multiple myeloma community, and their hopes for what this study can achieve for myeloma patients and their physicians.

In an interview with Targeted Oncology, C. Ola Landgren, MD, PhD, discussed the development of CAR T-cell therapy in the treatment landscape of multiple myeloma.

Updated findings from phase 3 APOLLO show an improvement in progression-free survival with daratumumabe plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone alone.

A Biologics License Application has been submitted to the FDA for the use of idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma

A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.

Irene Ghobrial, MD, discusses the importance of the data made available through the Multiple Myeloma Research Foundation’s CureCloud research study.

The FDA has accepted the supplemental New Drug Application seeking approval of selinexor as treatment of patients with multiple myeloma following at least 1 prior line of therapy.

“We are pleased the committee recognised the potential for belantamab mafodotin to help patients who have relapsed or refractory multiple myeloma, an incurable disease with limited treatment options."

Breakthrough data for systemic therapies in the treatment of various hematologic malignancies impressed attendees at the American Society of Clinical Oncology 2020 Virtual Scientific Program.

Paul G. Richardson, MD, discusses the response rates observed in the first-in-human phase 1 trial of CC-92480 and dexamethasone in patients with relapsed/refractory multiple myeloma.

Robert A. Vescio, MD, discussed two treatment options for a 51-year-old male patient with newly diagnosed multiple myeloma.

In an interview with Targeted Oncology, Phillipe Moreau, MD, discussed the findings from the IKEMA trial and what these date mean for the treatment landscape of relapsed multiple myeloma.

Saad Z. Usmani, MD, discusses the phase 2 SWOG 1211 trial investigating bortezomib, lenalidomide, and dexamethasone with or without elotuzumab for patients with newly diagnosed, high-risk multiple myeloma.

The FDA has announced plans to convene a meeting of the Oncologic Drugs Advisory Committee to review the Biologic License Application for belantamab mafodotin as treated of patients with relapsed or refractory multiple myeloma.

“We found that the genomic alterations with smoldering multiple myeloma are essentially the same as full-fledged myeloma. This suggests that by the time smoldering multiple myeloma is diagnosed, most of the molecular abnormalities found in myeloma have already occurred.”

Jesus Berdeja, MD, discusses the next steps for the chimeric antigen receptor T-cell therapy JNJ-4528 following the data from the phase 1b portion of the CARTITUDE-1 trial in patients with relapsed/refractory multiple myeloma.

Another treatment option would be a welcome change for these patients, who tend to have poor prognoses once they run out of treatment options, according to Saad Z. Usmani, MD. After becoming refractory to available therapies, median overall survival is 6-11 months.

“Ide-cel demonstrated frequent, deep, and durable responses in heavily pretreated, highly relapsed/refractory patients with myeloma. Overall, ide-cel provides an attractive option for the treatment of patients with triple-class exposed relapsed/refractory myeloma."

According to the lead study author Jesus G. Berdeja, MD, the overall response rate was 100%, with a stringent complete response rate of 86%. Further, the progression-free survival rate was 86% at 9 months.

"In this trial, we show deep and durable responses with single-agent [belantamab mafodotin] were sustained with longer follow-up in this relapsed/refractory multiple myeloma population."